Hepatitis B virus induced cirrhosis and hepatocarcinoma: pathogenesis and therapeutics
Exploration of Digestive Diseases · 21.02.2025
DOI: 10.37349/edd.2025.100565 ↗Kurz gefasst
Fachartikel in der Zeitschrift Exploration of Digestive Diseases, online erschienen am 21.02.2025. Verfasst von Juntian Yao und 2 weiteren Autor:innen. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 78 Literaturangaben.
Abstract (Originalsprache)
Hepatitis B virus (HBV) infection is a major risk factor of cirrhosis and hepatocellular carcinoma (HCC) worldwide. Pathogenesis of HBV-induced cirrhosis and HCC involves viral factors and virus-triggered local inflammatory and immune responses, the latter leading to progressive fibrosis, cirrhosis and carcinogenesis. Antiviral therapeutics suppress HBV replication and reduce the risks of cirrhosis and HCC. We discuss the current knowledge on the pathogenesis of HBV-induced cirrhosis and HCC, focusing on mechanisms of current and emerging antiviral therapeutics.
Zitieren
APA
Yao, J., Guo, J., & Xie, Y. (2025). Hepatitis B virus induced cirrhosis and hepatocarcinoma: pathogenesis and therapeutics. Exploration of Digestive Diseases. https://doi.org/10.37349/edd.2025.100565
Vancouver
Yao J, Guo J, Xie Y. Hepatitis B virus induced cirrhosis and hepatocarcinoma: pathogenesis and therapeutics. Exploration of Digestive Diseases. 2025. doi:10.37349/edd.2025.100565
BibTeX
@article{Yao2025,
author = {Yao, Juntian and Guo, Jinsheng and Xie, Youhua},
title = {Hepatitis B virus induced cirrhosis and hepatocarcinoma: pathogenesis and therapeutics},
journal = {Exploration of Digestive Diseases},
year = {2025},
doi = {10.37349/edd.2025.100565}
}
EUVIMED